+365.7%
ALAB vs MRNA
+35.7%
+330.0%
-63.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -6.9% | -3.6% | -3.4% | -6.8% |
| 7D | +3.2% | -9.0% | +12.2% | +3.6% |
| 30D | -13.6% | +137.2% | -150.7% | -21.0% |
| 3M | -16.6% | +194.8% | -211.4% | -28.4% |
| 6M | +142.3% | +167.2% | -24.9% | +111.6% |
| YTD | +73.6% | +375.9% | -302.2% | +30.0% |
| 1Y | +33.7% | +465.2% | -431.5% | -5.0% |
| All | +365.7% | +35.7% | +330.0% | +310.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling